Campbell & CO Investment Adviser LLC Acquires New Holdings in Trevi Therapeutics, Inc. $TRVI

Campbell & CO Investment Adviser LLC bought a new position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) during the 2nd quarter, Holdings Channel reports. The institutional investor bought 13,748 shares of the company’s stock, valued at approximately $75,000.

Other large investors have also recently bought and sold shares of the company. Octagon Capital Advisors LP purchased a new position in shares of Trevi Therapeutics during the 1st quarter valued at $20,895,000. Armistice Capital LLC bought a new stake in Trevi Therapeutics during the first quarter valued at $18,795,000. Affinity Asset Advisors LLC purchased a new position in Trevi Therapeutics during the first quarter worth about $7,862,000. Invesco Ltd. increased its stake in Trevi Therapeutics by 3,511.1% in the 1st quarter. Invesco Ltd. now owns 852,985 shares of the company’s stock worth $5,365,000 after acquiring an additional 829,364 shares during the last quarter. Finally, Millennium Management LLC raised its holdings in shares of Trevi Therapeutics by 356.3% in the 1st quarter. Millennium Management LLC now owns 823,249 shares of the company’s stock valued at $5,178,000 after acquiring an additional 642,830 shares in the last quarter. 95.76% of the stock is owned by institutional investors.

Trevi Therapeutics Stock Performance

Shares of TRVI opened at $11.31 on Wednesday. Trevi Therapeutics, Inc. has a fifty-two week low of $2.36 and a fifty-two week high of $12.30. The firm has a market cap of $1.45 billion, a price-to-earnings ratio of -30.57 and a beta of 0.67. The firm has a 50 day moving average price of $10.04 and a 200-day moving average price of $7.91.

Trevi Therapeutics (NASDAQ:TRVI) last issued its earnings results on Thursday, November 13th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.02. As a group, equities research analysts predict that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on TRVI shares. D. Boral Capital reissued a “buy” rating and set a $19.00 price objective on shares of Trevi Therapeutics in a report on Friday, November 14th. Needham & Company LLC cut their price target on shares of Trevi Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Raymond James Financial decreased their price target on shares of Trevi Therapeutics from $29.00 to $27.00 and set a “strong-buy” rating on the stock in a report on Friday, August 8th. Morgan Stanley lifted their price objective on shares of Trevi Therapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a report on Friday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Trevi Therapeutics in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $21.11.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.